Volume 64, Pages S131-S136 (November 2003) The impact of calcimimetics on mineral metabolism and secondary hyperparathyroidism in end-stage renal disease  Geoffrey A. Block  Kidney International  Volume 64, Pages S131-S136 (November 2003) DOI: 10.1046/j.1523-1755.64.s87.20.x Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 1 Mechanisms underlying secondary hyperparathyroidism (SHPT). Calcium is the key regulator of parathyroid hormone (PTH) secretion. Kidney International 2003 64, S131-S136DOI: (10.1046/j.1523-1755.64.s87.20.x) Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 2 Contrasting effects of vitamin D and calcimimetic compounds on the daily pattern of parathyroid hormone (PTH). Kidney International 2003 64, S131-S136DOI: (10.1046/j.1523-1755.64.s87.20.x) Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 3 Effect of calcimimetic on the sigmoidal Ca2+-parathyroid hormone (PTH) relationship. Calcimimetics result in a leftward shift of the set point, thereby resulting in greater PTH suppression at any level of ionized calcium. Kidney International 2003 64, S131-S136DOI: (10.1046/j.1523-1755.64.s87.20.x) Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 4 Shown is parathyroid hormone (PTH) suppression achieved with cinacalcet HCl during a 2-year trial in which patients were randomized to placebo or cinacalcet (up to 50mg/day or up to 100mg/day) during the first year and subsequently rolled over into open label therapy with cinacalcet at doses up to 180mg/day. Kidney International 2003 64, S131-S136DOI: (10.1046/j.1523-1755.64.s87.20.x) Copyright © 2003 International Society of Nephrology Terms and Conditions